Previous close | 97.00 |
Open | 94.74 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 94.74 - 94.74 |
52-week range | 90.12 - 109.00 |
Volume | |
Avg. volume | 43,791 |
Market cap | 197.27B |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | 21.53 |
EPS (TTM) | 4.40 |
Earnings date | 18 Jul 2024 |
Forward dividend & yield | 3.76 (3.97%) |
Ex-dividend date | 07 Mar 2024 |
1y target est | N/A |
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
** Commodities group Glencore is studying an approach for Anglo American, two sources said, a development that could spark a bidding war for the 107-year old mining company. ** U.S. private equity firm Bain Capital is looking at buying some key assets of French tech and software company Atos , reported French paper Les Echos on its website, citing sources.
Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said on Thursday. Mariana Oncology is working on novel radioligand cancer therapies (RLTs) that have not yet been tested on humans. "The transaction bolsters the Novartis RLT pipeline and expands the company’s research infrastructure and clinical supply capabilities," Novartis said in a statement.